Navigation Links
Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Date:6/12/2008

WALTHAM, Mass., June 12 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2008, ended March 31, 2008. Total revenue for fiscal year 2008 was $19,296,000 compared to total revenue of $14,074,000 for fiscal year 2007 ended March 31, 2007, an increase of $5,222,000 or 37%. Total revenue for the year consisted primarily of Protein A and SecreFlo(R) product revenue.

Operating expenses for fiscal year 2008, excluding the $40,170,000 net gain from litigation previously reported in our second quarter as a result of our settlement with ImClone Systems, Inc., were $23,574,000 compared to $15,900,000 in fiscal year 2007. The increase in operating expenses of $7,674,000 was primarily the result of legal expenses incurred in conjunction with both the ImClone Systems, Inc. and Bristol-Myers Squibb litigations, direct material expenses associated with the increase in revenue, and increased research and development spending.

Net income for the year was $37,107,000 or $1.18 per diluted share, compared to a net loss for fiscal 2007 of $889,000 or $0.03 per diluted share. Net income includes a net gain of $40,170,000 from the litigation settlement with ImClone during the second quarter of fiscal year 2008. Cash and marketable securities as of March 31, 2008 were $60,589,000 compared to $22,627,000 as of March 31, 2007.

"During the past year, we have successfully advanced our product pipeline, achieved strong revenue growth and settled our outstanding litigations with ImClone Systems, Inc. and Bristol-Myers Squibb, resulting in substantial new resources for the company," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "Our f
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
2. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
3. Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
4. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
5. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
6. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
7. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
8. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
9. Rosetta Genomics Reports First Quarter 2008 Financial Results
10. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
11. Advance Nanotech Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... BlueInGreen announces the ... sales network. The business venture will bring the ... Atlantic Provinces, exclusively through Resource Systems. , Since ... Canada’s premiere manufacturing representative firms, hosting a diverse ... and wastewater markets. More information on Resource Systems ...
(Date:3/3/2015)... March 3, 2015 Fried, Frank, Harris, Shriver ... Lewis has joined the Firm as a partner ... New York office. Mr. Lewis ... as well as other intellectual property and general litigation. ... Lewis represents both plaintiffs and defendants in a range ...
(Date:3/3/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or ... Expert Opinion on Biological Therapy , Dr. Michael ... , at the Henry Ford Hospital in ... (TB4) has the capacity to promote CNS and peripheral ... leading to neurological recovery in each case.  They pointed ...
(Date:3/3/2015)... IRVINE, Calif. , March 3, 2015 AtheroNova ... subsidiary, AtheroNova Operations, Inc., filed voluntary petitions under Chapter 11 ... Central District of California , ... 2, 2015. The Company,s Chapter 11 cases are expected to ... options, including a Bankruptcy Court supervised asset sale process, for ...
Breaking Biology Technology:BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4
... software flexibility , Detect Released Oligosaccharides Using the ... Angela R. Downs Deborah A. Greer Stan ... , We compared the Eagle Eye ... SE2000 gel imager system,for imaging Fluorophore-Assisted ...
... cyclic-AMP detection kit and adenylate cyclase,(AC) toxin ... Inc. , Xinping Yang and Timothy G. Kingan, ... Kit is a highly sensitive and specific,antibody-based assay ... cAMP. The assay is based on the competition ...
... transduction efficiency and gene expression in,virtually any target cell line ... ,Stratagene , We describe three new ViraPort retroviral reporter vectors: ... , ,and pFB-Luc ... to determine transduction efficiency and gene expression in,virtually any target ...
Cached Biology Technology:Detect Released Oligosaccharides Using the Eagle Eye II,Still Video Imaging System 2Detect Released Oligosaccharides Using the Eagle Eye II,Still Video Imaging System 3Detect Released Oligosaccharides Using the Eagle Eye II,Still Video Imaging System 4Enzyme Immunoassay for Studying Intracellular Levels of cAMP 2Enzyme Immunoassay for Studying Intracellular Levels of cAMP 3Enzyme Immunoassay for Studying Intracellular Levels of cAMP 4Enzyme Immunoassay for Studying Intracellular Levels of cAMP 5Enzyme Immunoassay for Studying Intracellular Levels of cAMP 6Versatile Reporter Vectors for Monitoring Viral Transduction 2Versatile Reporter Vectors for Monitoring Viral Transduction 3Versatile Reporter Vectors for Monitoring Viral Transduction 4Versatile Reporter Vectors for Monitoring Viral Transduction 5Versatile Reporter Vectors for Monitoring Viral Transduction 6
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
(Date:2/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ) ... Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, ... their offering. , In global ... anticipated to overtake North America ... towards IT security, government biometric based projects such ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... - NOVEMBER 6, 2013: In an ... a New York-based physician-researcher from the Touro College of Osteopathic ... for levels of a growth protein that could help predict ... an analysis of findings in prior published studies, Touro researcher ...
... Mo. Researchers from the University of Missouri have ... cancer, the fourth leading cause of cancer death in ... deaths each year in the United States, and kills ... years, according to the National Cancer Institute. ...
... and largest of its kind study focusing on the ... in JAMA Pediatrics . The "Teen Longitudinal ... the National Institutes of Health (NIH) and is being ... Children,s Hospital. Thomas H. Inge, MD, PhD, with ...
Cached Biology News:Breastfeeding as a possible deterrent to autism -- a clinical perspective 2Breastfeeding as a possible deterrent to autism -- a clinical perspective 3MU study finds more accurate method to diagnose pancreatic cancer 2Findings announced from landmark study on safety of adolescent bariatric surgery 2
... is a fluorescent counterstain which ... color. The bright blue fluorescence ... fluorochromes such as rhodamine, Cy3, ... can be used for fluorescent ...
Contact us for more information...
... Most sensitive silver stain. ... No stop baths or reversers ... lipids and polysaccharides. Linear ... to stain multiple gels per ...
... you to insert a transposable element of ... in vitro transposition. It uses TnsABC* Transposase ... DNA target. Target DNA may be a ... on your interests (6-8). If the insertion ...
Biology Products: